In Vivo Near-Infrared Two-Photon Imaging of Amyloid Plaques in Deep Brain of Alzheimer's Disease Mouse Model.
Congping ChenZhuoyi LiangBiao ZhouXuesong LiCaleb LuiNancy Y IpJianan Y QuPublished in: ACS chemical neuroscience (2018)
Abnormal deposition of brain amyloid is a major hallmark of Alzheimer's disease (AD). The toxic extracellular amyloid plaques originating from the aberrant aggregation of beta-amyloid (Aβ) protein are considered to be the major cause of clinical deficits such as memory loss and cognitive impairment. Two-photon excited fluorescence (TPEF) microscopy provides high spatial resolution, minimal invasiveness, and long-term monitoring capability. TPEF imaging of amyloid plaques in AD transgenic mice models has greatly facilitated studies of the AD pathological mechanism. However, the imaging of deep cortical layers is still hampered by the conventional amyloid probes with short excitation/emission wavelength. In this work, we report that a near-infrared (NIR) probe, named CRANAD-3, is far superior for deep in vivo TPEF imaging of brain amyloid in comparison with the commonly used short-wavelength probe. Our findings show that the major interference for TPEF signal of the NIR probe is from the autofluorescence of lipofuscin, the "aging-pigment" in the brain. To eliminate the interference, we characterized the lipofuscin fluorescence in the aged brains of AD mice and found that it has unique broad emission and short lifetime. The lipofuscin signal can be clearly separated from the fluorescence of CRANAD-3 and fluorescent protein via a ratio-based unmixing method. Our results demonstrate the great advantages of NIR probes for in vivo deep-tissue imaging of amyloid plaques in AD.
Keyphrases
- living cells
- high resolution
- single molecule
- fluorescence imaging
- fluorescent probe
- white matter
- mouse model
- cognitive impairment
- quantum dots
- photodynamic therapy
- resting state
- small molecule
- traumatic brain injury
- energy transfer
- cognitive decline
- type diabetes
- cerebral ischemia
- protein protein
- mass spectrometry
- high throughput
- metabolic syndrome
- brain injury
- subarachnoid hemorrhage
- drug release
- mild cognitive impairment
- case control
- solid state